<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599960</url>
  </required_header>
  <id_info>
    <org_study_id>LpDessai</org_study_id>
    <nct_id>NCT03599960</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Patients With Newly Diagnosed BPDCN</brief_title>
  <acronym>LpDessai</acronym>
  <official_title>Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMR1098, EFS BFC, BESANCON</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inserm CIC1431, CHU Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with suspected BPDCN and meeting eligibility criteria will be enrolled in the study.
      First, BPDCN diagnosis will be confirmed by anatomic pathology (Dr Petrella T, Montreal) and
      cytologic plus immunophenotyping analysis (Pr Garnache Ottou F, UMR1098 BESANCON). Patients
      will then receive three 21 days cycles of a combination of chemotherapy
      (Ida/Metho/L-asp/Dex), followed by an evaluation. Patients with complete response (CR) or
      complete response with incomplete bone marrow recovery (CRi) will undergo an allo- or
      auto-SCT and those who are not eligible to the transplantation will have successive 28 days
      cycles of chemotherapy (Metho/L-asp/Dex). Patients who did not respond to the treatment will
      be treated by physicians. All patients will be followed for 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will receive 3 cycles of a combination of chemotherapy (Met/Ida/L-Asp/Dex)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete response after 3 cycles of chemotherapy</measure>
    <time_frame>12 weeks (3 weeks after 3 cycles of chemotherapy (each cycle is 21 days))</time_frame>
    <description>Proportion of patients with complete response after 3 cycles of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with response (complete or partial) after 3 cycles of chemotherapy</measure>
    <time_frame>12 weeks (3 weeks after 3 cycles of chemotherapy (each cycle is 21 days))</time_frame>
    <description>Proportion of patients with response (complete or partial) after 3 cycles of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Relapse-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual L-asparaginase activity</measure>
    <time_frame>12 weeks (Day 8 of each chemotherapy cycle (each cycle is 21 days))</time_frame>
    <description>Residual L-asparaginase activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-L-asparaginase antibodies levels</measure>
    <time_frame>12 weeks (Day 8 of each chemotherapy cycle (each cycle is 21 days))</time_frame>
    <description>Evaluation of the titer of the anti-asparaginase antibody</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal residual disease analysis</measure>
    <time_frame>24 months</time_frame>
    <description>presence of PDC cell blast (CD56 +, NG2 +, BDCA2low, BDCA4low, CD123low, cTCL1high as measured by flow cytometry)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Idarubicin 12mg/m2 IV at D1
Methotrexate : 3000 mg/m2 IV at D1 (24H infusion, dosing modification (1500 mg/m²) if CrCl between 50 to 80ml/min or Age ≥70y, alkaline hydration, leucovorin rescue)
L-asparaginase (KIDROLASE) : 6000 units/m2 IV at D2, 4, 6, 8 (switch to Erwinia asparaginase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)
Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥70y)</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed BPDCN established by a blood or bone marrow immunophenotypic diagnosis
             by flow cytometric and/or by the anatomic pathology study of a skin biopsy using
             validated diagnostic criteria (Swerdlow SH CE et al., World Health Organisation
             Classification of Tumors, 2008; Garnache-Ottou et al., 2009; Angelot et al., 2012;
             Julia et al., 2014) or patients with confirmed isolated skin lesion.

          -  18 years of age or older

          -  No prior cytotoxic therapy except &lt;2 week of corticosteroids or hydroxyurea

          -  ECOG &lt;2

          -  Written informed consent

          -  Affiliation to the French social security scheme

        Exclusion Criteria:

          -  Cardiac contra-indication to anthracyclines: cardiac dysfunction events (NYHA grade 3
             or 4 and/or LVEF&lt;50%)

          -  Hepatocellular abnormalities except if considered related to the BPDCN:

               1. ASAT (SGOT) and/or ALAT (SGPT) &gt; 5 x ULN

               2. Total bilirubin ≥ 2.5 x ULN

          -  Creatinine level &gt;1.5x ULN or creatinine clearance &lt;50 mL/mn

          -  Prior thrombotic event

          -  Active hepatitis B or C virus infection

          -  HIV positive

          -  Serious medical or psychiatric illness that could interfere with the completion of
             treatment

          -  Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

          -  Pregnant and lactating female patients

          -  Patients diagnosed with or treated for another malignancy within 2 years before study
             enrollment or with residual disease (basal cell carcinoma or cervical carcinoma in
             situ patients may be enrolled if they have undergone complete resection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric DECONINCK, MD, PhD</last_name>
    <phone>+3381668166</phone>
    <email>edeconinck@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GRUSON Bérengère, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DECONINCK ERIC, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

